Patents by Inventor Lukasz KIELPINSKI

Lukasz KIELPINSKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230054720
    Abstract: The present invention relates to antisense LNA oligonucleotides (oligomers) complementary to ATXN3 pre-mRNA sequences, which are capable of inhibiting the expression of ATXN3 protein.
    Type: Application
    Filed: December 2, 2021
    Publication date: February 23, 2023
    Inventors: Heidi Rye Hudlebusch, Lykke Pedersen, Erik Funder, Lukasz Kielpinski, Christoffer Sondergaard, Alexander Herbert Stephan, Mads Manso
  • Patent number: 11485975
    Abstract: The present invention relates to oligonucleotides that are complementary to and modulate the expression of TMEM106B. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurological disorders using the oligonucleotide.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: November 1, 2022
    Assignee: Genentech, Inc.
    Inventors: Peter Hagedorn, Marianne L. Jensen, Lukasz Kielpinski, Amy Easton, Benny Chih
  • Publication number: 20220177883
    Abstract: The present invention relates to antisense LNA oligonucleotides (oligomers) complementary to ATXN3 pre-mRNA sequences, which are capable of inhibiting the expression of ATXN3 protein. Inhibition of ATXN3 expression is beneficial for the treatment of spinocerebellar ataxia.
    Type: Application
    Filed: December 2, 2021
    Publication date: June 9, 2022
    Inventors: Heidi Rye Hudlebusch, Lykke Pedersen, Erik Funder, Lukasz Kielpinski, Christoffer Sondergaard, Alexander Herbert Stephan
  • Publication number: 20220002796
    Abstract: The invention relates to the field of therapeutic oligonucleotide analytics, and provides methods for primer based parallel sequencing of therapeutic oligonucleotides which provide sequence based quality information which may be used in conjunction with or in place of present chromatography or mass spectroscopic methods, and may be used, for example, in oligonucleotide therapeutic discovery, manufacture, quality assurance, therapeutic development, and patient monitoring.
    Type: Application
    Filed: May 6, 2019
    Publication date: January 6, 2022
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Mads JENSEN, Jonas VIKESAA, Lukasz KIELPINSKI, Lars JOENSON, Filippo SLADOJEVICH
  • Publication number: 20210269851
    Abstract: The invention relates to the field of therapeutic oligonucleotide analytics and discovery, and provides methods for primer based parallel sequencing of modified oligonucleotides which provide sequence based quality information which may be used in oligonucleotide therapeutic discovery, manufacture, quality assurance, therapeutic development, and patient monitoring.
    Type: Application
    Filed: May 6, 2019
    Publication date: September 2, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Mads JENSEN, Lars JOENSON, Lukasz KIELPINSKI, Jonas VIKESAA, Filippo SLADOJEVICH
  • Publication number: 20210270845
    Abstract: The invention relates to the field of secondary markers for microRNA activity, and in particular the invention relates to the identification of Serpine1 as a mRNA which is repressed by microRNA-134 in neuronal cells, and the use of Serpine1 mRNA or protein as a biomarker for microRNA-134 modulation, such as a biomarker for antisense oligonucleotide inhibitors of microRNA-134.
    Type: Application
    Filed: February 23, 2021
    Publication date: September 2, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Jesper Worm, Lukasz Kielpinski
  • Publication number: 20210071247
    Abstract: The invention relates to the field of therapeutic oligonucleotide analytics and discovery, and provides methods for primer based parallel sequencing of modified oligonucleotides which provide sequence based quality information which may be used in oligonucleotide therapeutic discovery, manufacture, quality assurance, therapeutic development, and patient monitoring.
    Type: Application
    Filed: May 6, 2019
    Publication date: March 11, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Mads JENSEN, Jonas VIKESAA, Lukasz KIELPINSKI, Lars JOENSON, Filippo SLADOJEVICH
  • Publication number: 20210054383
    Abstract: The present invention relates to oligonucleotides that are complementary to and modulate the expression of TMEM106B. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurological disorders using the oligonucleotide.
    Type: Application
    Filed: August 6, 2020
    Publication date: February 25, 2021
    Inventors: Peter HAGEDORN, Marianne L. JENSEN, Lukasz KIELPINSKI, Amy EASTON, Benny CHIH
  • Publication number: 20190284621
    Abstract: The present invention relates to the detection of therapeutic modified oligonucleotides in biological samples and an adaptor oligonucleotide (capture probe) which enables a quantitative PCR based detection method and the sequencing of modified oligonucleotides. The invention provides novel adaptor probes for use in detecting therapeutic oligonucleotides and for in vivo discovery of preferred therapeutic oligonucleotide sequences.
    Type: Application
    Filed: November 9, 2017
    Publication date: September 19, 2019
    Inventors: Mads Aaboe JENSEN, Lars JOENSON, Lukasz KIELPINSKI, Morten LINDOW, Jonas VIKESAA